The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Novartis (Inst); Phio Pharmaceuticals (Inst)
 
Caroline Dutriaux
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
 
Felix Boakye Oppong
No Relationships to Disclose
 
Michal Kicinski
Research Funding - BMS (Inst); Immunocore (Inst); Janssen (Inst); Merck (Inst); Pierre Fabre (Inst)
 
Emilie Routier
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; MSD Oncology; Pierre Fabre; Sanofi/Regeneron; Sun Pharma
 
Eve-Marie Neidhardt
Consulting or Advisory Role - Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Le cancer.fr; Pierre Fabre
 
Xavier Durando
No Relationships to Disclose
 
Barouyr Baroudjian
Honoraria - BMS; MSD; Novartis; Pierre Fabre; Pierre Fabre; Sanofi
Consulting or Advisory Role - BMS; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - BMS; MSD; Pierre Fabre
 
Philippe Saiag
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche/Genentech; Sanofi
Research Funding - Pierre Fabre
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; pierre fabre; Roche
 
Caroline Gaudy-Marqueste
Honoraria - BMS france; Pierre Fabre
Consulting or Advisory Role - Pierre Fabre
Research Funding - BMS, Pfizer, Amgen, GSK, Roche, Novartis, Pierre Fabre, Replimune, MSD, Janssen, Kartos, IFX, Huyabio, Regeneron, IO Biotech, Philogen, Sotio, Kinnate, Astra Zenecca, Cytovation (Inst)
Travel, Accommodations, Expenses - BMS France; MSD Oncology; Pierre Fabre
 
Paolo Antonio Ascierto
Consulting or Advisory Role - 4SC; Anaveon; AstraZeneca; Bayer; Bio-AI Health; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Erasca, Inc; Idera; Immunocore; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Ultimovacs; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bio-AI Health; MSD Oncology; Pfizer; Pierre Fabre; Replimune
 
Ana Maria Arance
Consulting or Advisory Role - BioNTech SE; BMS; MSD; Novartis; Pierre Fabre; Roche
Speakers' Bureau - BMS; MSD; Novartis; Pierre Fabre; Roche
Research Funding - BioNTech SE (Inst); BMS (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; MSD
 
Michelangelo Russillo
Honoraria - bristol; MSD Oncology; Novartis Italy; Pierre Fabre
Research Funding - BioNTech (Inst); Novartis Italy (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Novartis; Pierre Fabre
 
Jean-Luc Perrot
No Relationships to Disclose
 
Anne-sophie Govaerts
No Relationships to Disclose
 
Emanuel Bührer
Stock and Other Ownership Interests - Alcon (I); Galenica (I); Novartis (I); Roche (I); Sandoz (I)
 
Bastian Schilling
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer/EMD Serono; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; Novartis; Pierre Fabre; Sanofi Aventis GmbH; Sun Pharma
Research Funding - Novartis (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Pierre Fabre
 
Mario Mandala
Honoraria - Bristol-Myers Squibb/Sanofi; MSD Oncology; Novartis; Pierre Fabre; Sanofi/Aventis
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre
Research Funding - Novartis (Inst)
 
Paul Lorigan
Stock and Other Ownership Interests - Supportive Care; The Christie Private Care
Honoraria - BMS; Merck; MLA Dx; MSD; NeraCare GmbH; Ultimovacs
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; NeraCare GmbH
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme
Research Funding - BMS (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Alexander Christopher Jonathan van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst); MSD Oncology (Inst); NeraCare GmbH; Novartis (Inst); Pierre Fabre (Inst); Provectus Biopharmaceuticals; Sanofi (Inst); Sirius Medical (Inst); Skyline Diagnostics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis